Gerber Kawasaki Wealth & Investment Management Increases Position in Eli Lilly and Company $LLY

Gerber Kawasaki Wealth & Investment Management increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 22.3% during the second quarter, Holdings Channel reports. The fund owned 9,472 shares of the company’s stock after acquiring an additional 1,727 shares during the quarter. Gerber Kawasaki Wealth & Investment Management’s holdings in Eli Lilly and Company were worth $7,384,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company in the first quarter valued at $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new stake in Eli Lilly and Company in the 2nd quarter valued at about $27,000. Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $31,000. Bare Financial Services Inc lifted its holdings in shares of Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 29 shares during the period. Finally, Blume Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after acquiring an additional 14 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

LLY stock opened at $1,009.26 on Monday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The firm has a market cap of $954.13 billion, a P/E ratio of 49.38, a price-to-earnings-growth ratio of 1.12 and a beta of 0.37. The stock has a 50-day simple moving average of $918.84 and a 200-day simple moving average of $810.35.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the company posted $1.18 EPS. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on LLY. BMO Capital Markets set a $1,200.00 price target on shares of Eli Lilly and Company in a research report on Thursday. Morgan Stanley upped their price objective on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Scotiabank initiated coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price target for the company. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Finally, Weiss Ratings raised Eli Lilly and Company from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,087.32.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.